阿托伐他汀联合康柏西普治疗视网膜静脉阻塞继发黄斑水肿合并颈动脉斑块患者的临床效果:前瞻性随机对照试验研究方案
本研究为前瞻性随机对照试验,计划纳入64例视网膜分支或中央静脉阻塞继发黄斑水肿且合并颈动脉斑块的患者,按1:1随机分为对照组和试验组。对照组接受玻璃体腔注射康柏西普每月1次共3个月,随后12个月内每月评估并按需注射;试验组在对照组治疗基础上联合口服阿托伐他汀20 mg每日一次。主要观察12个月随访期间中央子区厚度、最佳矫正视力、注射次数及不良事件发生率。
要点
- 试验组在康柏西普基础上联合口服阿托伐他汀20 mg每日一次。
- 对照组康柏西普每月注射共3个月,随后12个月内每月评估并按需注射。
- 主要结局包括12个月随访期间的中央子区厚度、最佳矫正视力、注射次数及不良事件。
核心结论
- 研究方案旨在观察阿托伐他汀联合玻璃体腔注射康柏西普治疗分支或中央视网膜静脉阻塞继发黄斑水肿合并颈动脉斑块患者的临床效果。
研究设计与样本
- 前瞻性随机对照临床试验,计划纳入64例分支或中央视网膜静脉阻塞继发黄斑水肿合并颈动脉斑块患者,按1:1比例随机分配至对照组和试验组。
关键数值与推荐
- 对照组接受玻璃体腔注射康柏西普每月1次共3个月,随后12个月内每月评估并按需注射。
- 试验组接受口服阿托伐他汀20 mg每日一次联合对照组治疗。
- 若最佳矫正视力下降超过5个早期糖尿病视网膜病变研究组字母(一行)或中央子区厚度增加100 μm(或较前次访视增加10%),则进行玻璃体腔再注射。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) drugs have been widely used in patients with macular edema (ME) secondary to retinal vein occlusion (RVO); however, recurrence is a major concern. This study aims to observe the clinical effects of atorvastatin and intravitreal therapy in the treatment of patients with branch or central RVO-ME and coexistent carotid plaques (CP). METHODS AND ANALYSIS: A prospective randomized controlled clinical trial will be conducted. Sixty-four patients diagnosed with branch or central RVO-ME and coexistent CP will be enrolled and randomly allocated in a 1:1 ratio to the control and experimental groups. The control group will be treated with intravitreal conbercept monthly for 3 months, followed by monthly evaluation and injection of pro re nata (PRN) for 12 months, while the experimental group will be treated with oral atorvastatin 20 mg daily combined with the control group treatment. If a drop of best-corrected visual acuity (BCVA) is more than five Early Treatment Diabetic Retinopathy Study (ETDRS) letters (one line) or an increment in central subfield thickness (CSFT) of 100 μm (or a 10% increment from the previous visit), intravitreal re-treatment will be performed. Outcome measurements include CSFT, BCVA, number of injections, and incidence of adverse events during the 12-month follow-up period. Differences between groups will be evaluated using Student's t-test, and comparisons between groups will be evaluated using repeated-measures analysis of variance. ETHICS AND DISSEMINATION: The study has been approved by the Institutional Review Board of Nanjing Lishui People's Hospital, Nanjing, China (approval number 2023KY0418-12, dated 18 April 2023), and has been registered on chictr.org.cn. Written informed consent will be collected from each patient and the results of this trial will be submitted to a peer-reviewed journal. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR2300071359. Registered on 12 May 2023.
引用
- Yao B, Wang B, Yang J, et al. Clinical effects of atorvastatin combined with conbercept in the treatment of patients with macular edema secondary to retinal vein occlusion and carotid plaque: study protocol for a prospective randomized controlled trial. Trials. 2024. PMID: 38589960. doi:10.1186/s13063-024-08082-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。